10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2020 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 10, 2021) | ||
| (In Millions) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 14,546 | 12,346 |
| Marketable debt securities, current | 1,285 | 3,047 |
| Receivables | 8,501 | 7,685 |
| Inventories | 2,074 | 4,293 |
| Other current assets | 3,786 | 1,983 |
| Total Current Assets | 30,192 | 29,354 |
| Property, plant and equipment | 5,886 | 6,252 |
| Goodwill | 20,547 | 22,488 |
| Other intangible assets | 53,243 | 63,969 |
| Deferred Tax Assets, Net of Valuation Allowance, Noncurrent | 1,161 | 510 |
| Marketable debt securities, noncurrent | 433 | 767 |
| Other Assets, Noncurrent | 7,019 | 6,604 |
| Total Assets | 118,481 | 129,944 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 2,340 | 3,346 |
| Accounts payable | 2,713 | 2,445 |
| Other current liabilities | 14,027 | 12,513 |
| Total Current Liabilities | 19,080 | 18,304 |
| Deferred Income Tax Liabilities, Net | 5,407 | 6,454 |
| Long-term debt | 48,336 | 43,387 |
| Other Liabilities, Noncurrent | 7,776 | 10,101 |
| Total Liabilities | 80,599 | 78,246 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders' Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 3,484 in 2020 and 3,568 in 2019, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2020 and 2019 | 292 | 292 |
| Capital in excess of par value of stock | 44,325 | 43,709 |
| Accumulated other comprehensive loss | (1,839) | (1,520) |
| Retained earnings | 21,281 | 34,474 |
| Less cost of treasury stock - 679 million common shares in 2020 and 672 million common shares in 2019 | (26,237) | (25,357) |
| Total Bristol-Myers Squibb Company Shareholders' Equity | 37,822 | 51,598 |
| Noncontrolling interest | 60 | 100 |
| Total Equity | 37,882 | 51,698 |
| Total Liabilities and Equity | 118,481 | 129,944 |
| Preferred Stock, Shares Outstanding | 0 | 0 |
| Preferred Stock, Par or Stated Value Per Share | 1 | 1 |
| Preferred Stock, Shares Authorized | 10 | 10 |
| Preferred Stock, Shares Issued | 0 | 0 |
| Preferred Stock, Liquidation Preference Per Share | 50 | 50 |
| Common Stock, Par or Stated Value Per Share | 0 | 0 |
| Common Stock, Shares Authorized | 4,500 | 4,500 |
| Common Stock, Shares Issued | 2,900 | 2,900 |
| Treasury Stock, Shares | 679 | 672 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |